EUVIMEDOpdag EUVIMED
Scoping ReviewOpen access · CC BY 4.0

Assessing efficacy and safety of replacement fluids in therapeutic plasma exchange: A systematic scoping review of outcome measures used

Ruchika Kohli iD, Louise J Geneen, Susan J Brunskill, Carolyn Doree, Lise Estcourt, Stephan E J Chee, Raya Al-Bader, Wing Y C Sin, Peter MacCallum, Laura Green

Journal of Clinical Apheresis · 2022-10 · 37 (5) · 438-448

DOI: 10.1002/jca.21996 ↗

At a glance

Scoping Review in Journal of Clinical Apheresis, published online on 2022-06-21. Written by Ruchika Kohli and 9 co-authors. Institution: Wolfson Institute of Population Health, Queen Mary University of London, London. Major MEDLINE topics: Plasma Exchange, Purpura, Thrombotic Thrombocytopenic. Cited 16 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHS Blood and Transplant Trust Fund, Queen Mary University of London, Systematic Review Initiative, NHS Blood and Transplant, funded by UK Blood Services.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

The aim of this systematic scoping review is to identify and categorize the outcome measures that have been reported in clinical studies, where therapeutic plasma exchange (TPE) has been used as an intervention in any clinical settings, excluding thrombotic thrombocytopenic purpura (TTP).

Methods

We searched electronic databases using a predefined search strategy from inception to October 9, 2020. Two reviewers independently screened and extracted data.

Results

We included 42 studies (37 RCTs and 5 prospective cohort studies) grouped into six main categories (neurology, immunology, renal, rheumatology, hematology, and dermatology). Primary outcomes were defined in eight studies (19%, 8/42) and were categorized as efficacy (five studies) or patient reported outcomes (three studies). A power calculation was reported in six studies (75%, 6/8): five neurology studies (mainly patient reported outcomes) and a single immunological study (efficacy outcome). Disease‐specific efficacy outcomes were dependent on the clinical setting of the population receiving TPE. Most of the trials (43%, 18/42) were undertaken in patients with neurology conditions where clear, disease‐specific, clinical outcome measures were used, including neurological disability scales (11/18, 61%), change in neurological examination (9/18, 50%), and functional improvement scores (7/18, 39%). For other conditions, the reporting of disease‐specific outcomes was poorly reported. Safety outcomes were mainly related to replacement fluid type rather than being disease‐specific. The most common outcome reported was hypotension (19%, 8/42), and this was primarily in patients exchanged with albumin.

Conclusion

Future clinical studies to determine which fluid replacement option is most efficacious and safe should use disease‐specific outcomes, as a trial in one therapeutic area may not necessarily translate to another therapeutic area. Patient reported outcomes are not universally reported for all disease areas. Safety measures focused primarily on fluid safety.

Subjects

MeSH terms (MEDLINE)

Plasma ExchangePurpura, Thrombotic ThrombocytopenicAlbuminsHumansOutcome Assessment, Health CareProspective Studies

Author keywords

immunologyneurologyplasma exchange

Substances

Albumins

Authors and institutions

  • Wolfson Institute of Population Health, Queen Mary University of London, London.
  • Systematic Review Initiative, National Health Service Blood and Transplant, Oxford, UK.
  • Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Barts and the London, School of Medicine and Dentistry, London, UK.
  • East London NHS Foundation Trust, London, UK.
  • Barts Health NHS Trust, London, UK.

ORCID profiles: Ruchika Kohli

Funding

  • NHS Blood and Transplant Trust Fund
  • Queen Mary University of London
  • Systematic Review Initiative, NHS Blood and Transplant, funded by UK Blood Services

Cite

APA

Kohli, R., Geneen, L. J., Brunskill, S. J., Doree, C., Estcourt, L., Chee, S. E. J., Al-Bader, R., Sin, W. Y. C., MacCallum, P., & Green, L. (2022). Assessing efficacy and safety of replacement fluids in therapeutic plasma exchange: A systematic scoping review of outcome measures used. Journal of Clinical Apheresis, 37(5), 438-448. https://doi.org/10.1002/jca.21996

Vancouver

Kohli R, Geneen LJ, Brunskill SJ, Doree C, Estcourt L, Chee SEJ, et al. Assessing efficacy and safety of replacement fluids in therapeutic plasma exchange: A systematic scoping review of outcome measures used. Journal of Clinical Apheresis. 2022;37(5):438-448. doi:10.1002/jca.21996

BibTeX
@article{Kohli2022,
  author = {Kohli, Ruchika and Geneen, Louise J and Brunskill, Susan J and Doree, Carolyn and Estcourt, Lise and Chee, Stephan E J and Al-Bader, Raya and Sin, Wing Y C and MacCallum, Peter and Green, Laura},
  title = {Assessing efficacy and safety of replacement fluids in therapeutic plasma exchange: A systematic scoping review of outcome measures used},
  journal = {Journal of Clinical Apheresis},
  year = {2022},
  volume = {37},
  number = {5},
  pages = {438--448},
  doi = {10.1002/jca.21996}
}
Start for free →